Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, NextCure's Enterprise Value is $-49.27 Mil.
NextCure's EBIT for the trailing twelve months (TTM) ended in Sep. 2024 was $-60.54 Mil. Therefore, NextCure's EV-to-EBIT ratio for today is 0.81.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, NextCure's Enterprise Value is $-49.27 Mil.
NextCure's EBITDA for the trailing twelve months (TTM) ended in Sep. 2024 was $-57.53 Mil. Therefore, NextCure's EV-to-EBITDA ratio for today is 0.86.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, NextCure's Enterprise Value is $-49.27 Mil.
NextCure's Revenue for the trailing twelve months (TTM) ended in Sep. 2024 was $0.00 Mil. Therefore, NextCure's EV-to-Revenue ratio for today is .
EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, NextCure's Enterprise Value is $-49.27 Mil.
NextCure's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 was $-45.03 Mil. Therefore, NextCure's EV-to-FCF ratio for today is 1.09.
NextCure Enterprise Value Historical Data
The historical data trend for NextCure's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of NextCure's Enterprise Value
For the Biotechnology subindustry, NextCure's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NextCure's Enterprise Value Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, NextCure's Enterprise Value distribution charts can be found below:
* The bar in red indicates where NextCure's Enterprise Value falls into.
NextCure Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
NextCure's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NextCure (NAS:NXTC) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
NextCure's current Enterprise Value is $-49.27 Mil.
NextCure's EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-60.54 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
NextCure's current Enterprise Value is $-49.27 Mil.
NextCure's EBITDA for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-57.53 Mil.
NextCure's current Enterprise Value is $-49.27 Mil.
NextCure's Revenue for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
NextCure's current Enterprise Value is $-49.27 Mil.
NextCure's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-45.03 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NextCure Enterprise Value Related Terms
Thank you for viewing the detailed overview of NextCure's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases, and NC181, for Alzheimer's disease.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NXTC has been successfully added to your 